BioInvent International has received authorization to proceed from the Swedish Medical Product Agency for a new clinical trial that will study the activity of its proprietary monoclonal antibody BI-1206.
The new clinical study is a Phase l/lla, dose escalation, consecutive-cohort, open-label study of BI-1206 in combination with rituximab in patients with indolent relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). The trial is now open for recruitment and is estimated to recruit approximately 30 patients. The targeted sub-indications are mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The clinical evaluation of BI-1206 is ongoing in a parallel Phase I/IIa study in the UK, which is performed by Cancer Research UK.
“The decision to expand the clinical development program was taken based on pre-clinical data demonstrating that BI-1206 has the capacity to strongly enhance the activity of rituximab, a major component of the current standard treatment of NHL. By directly testing the combination of BI-1206 and rituximab, the new trial will speed-up the development of this promising drug candidate”, says Andres McAllister, CMO at BioInvent. “The results from this trial are expected to add value to the program and support discussions with potential partners in preparation for future clinical development and commercialization”, says Björn Frendéus, acting CEO at BioInvent.
Photo of Björn Frendéus, CEO BioInvent